Press Releases

Date Title and Summary Additional Formats
Toggle Summary Data From an Investigator-Initiated Phase 2 Study of NewLink Genetics' HyperAcute® Melanoma Immunotherapy Published in 2012 ASCO Annual Meeting Abstracts
HyperAcute Melanoma Demonstrates Activity in Stage III and Stage IV Patients
View HTML
Toggle Summary NewLink Genetics to Present at the Jefferies 2012 Global Healthcare Conference
AMES, Iowa, May 30, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics (Nasdaq:NLNK) announced today that Dr. Charles Link, Chairman and Chief Executive Officer, will present at the Jefferies 2012 Global Healthcare Conference in New York on Wednesday, June 6, 2012, at 4:30 p.m. (EDT). Dr.
View HTML
Toggle Summary Data From NewLink Genetics Phase 2 Trial of Its HyperAcute(R) Pancreas (Algenpantucel-L) Immunotherapy to be Presented at the 2012 Digestive Disease Week
Algenpantucel-L Immunotherapy Phase 2 Data Featured in Plenary Session at 53rd Annual Meeting of the Society for Surgery of the Alimentary Tract and Will be Published in the Journal of Gastrointestinal Surgery
View HTML
Toggle Summary NewLink Genetics Corporation Reports First Quarter 2012 Financial Results
AMES, Iowa, May 10, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today reported consolidated financial results for the first quarter of 2012, and provided an update on the
View HTML
Toggle Summary NewLink Genetics Receives Notice of Allowance From USPTO for New Patent Broadly Covering Its D-1MT IDO Pathway Inhibitor
AMES, Iowa, April 24, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that the United States Patent & Trademark Office (USPTO) has allowed broad claims to oral pharmaceutical compositions comprising 1-methyl-D-tryptophan (D-1MT) (US Serial No.
View HTML
Toggle Summary NewLink Genetics Receives Notice of Allowance From the Japan Patent Office for New Patent Broadly Covering Its HyperAcute(R) Cancer Immunotherapy Products
AMES, Iowa, April 17, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that the Japan Patent Office has issued a notice of allowance for a patent entitled "Antitumor Vaccination Using Allogeneic Tumor Cells Expressing Alpha (1,3)-Galactosyltransferase," which
View HTML
Toggle Summary NewLink Genetics and Its CEO Are Recognized as High-Tech Leaders by the Technology Association of Iowa
AMES, Iowa, April 13, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), today announced that NewLink and its Chief Executive Officer, Dr. Charles Link, each received one of the 2012 Prometheus Awards granted each year by the Technology Association of Iowa.
View HTML
Toggle Summary NewLink Genetics to Present Data at the American Society of Clinical Oncology and Digestive Disease Week Annual Meetings
AMES, Iowa, April 11, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that data from its HyperAcute® Pancreas immunotherapy and its HyperAcute® Lung immunotherapy as well as its D-1MT IDO pathway inhibitor will be presented at the upcoming American Society of
View HTML
Toggle Summary NewLink Genetics Corporation Reports Fourth Quarter and Full-Year 2011 Financial Results
Conference Call Scheduled for 5:00 pm EDT March 29, 2012
View HTML
Toggle Summary NewLink Enters Into an Agreement Converting Its $6 Million Forgivable Loan to a Royalty Interest
AMES, Iowa, March 27, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics (Nasdaq:NLNK) announced today that it has entered into an agreement with the Iowa Economic Development Authority ("IEDA"). After reviewing NewLink's accomplishments on its milestones and its significant contributions to the State of
View HTML